Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
Issued Date
2023-08-01
Resource Type
eISSN
20597029
Scopus ID
2-s2.0-85163022518
Journal Title
ESMO Open
Volume
8
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
ESMO Open Vol.8 No.4 (2023)
Suggested Citation
Loong H.H., Shimizu T., Prawira A., Tan A.C., Tran B., Day D., Tan D.S.P., Ting F.I.L., Chiu J.W., Hui M., Wilson M.K., Prasongsook N., Koyama T., Reungwetwattana T., Tan T.J., Heong V., Voon P.J., Park S., Tan I.B., Chan S.L., Tan D.S.W. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. ESMO Open Vol.8 No.4 (2023). doi:10.1016/j.esmoop.2023.101586 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87751
Title
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
Author's Affiliation
Hospital Umum Sarawak
Peter Maccallum Cancer Centre
National Cancer Centre, Singapore
Wakayama Medical University
Samsung Medical Center, Sungkyunkwan university
Monash University
National Cancer Center Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Auckland City Hospital
Phramongkutklao College of Medicine
The University of Hong Kong
Chinese University of Hong Kong
Tan Tock Seng Hospital
Prince of Wales Hospital
National University Cancer Institute
Chris O'Brien Lifehouse
Dr. Pablo O. Torre Memorial Hospital
Peter Maccallum Cancer Centre
National Cancer Centre, Singapore
Wakayama Medical University
Samsung Medical Center, Sungkyunkwan university
Monash University
National Cancer Center Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Auckland City Hospital
Phramongkutklao College of Medicine
The University of Hong Kong
Chinese University of Hong Kong
Tan Tock Seng Hospital
Prince of Wales Hospital
National University Cancer Institute
Chris O'Brien Lifehouse
Dr. Pablo O. Torre Memorial Hospital
Other Contributor(s)
Abstract
Introduction: Next-generation sequencing (NGS) diagnostics have shown clinical utility in predicting survival benefits in patients with certain cancer types who are undergoing targeted drug therapies. Currently, there are no guidelines or recommendations for the use of NGS in patients with metastatic cancer from an Asian perspective. In this article, we present the Asia-Pacific Oncology Drug Development Consortium (APODDC) recommendations for the clinical use of NGS in metastatic cancers. Methods: The APODDC set up a group of experts in the field of clinical cancer genomics to (i) understand the current NGS landscape for metastatic cancers in the Asia-Pacific (APAC) region; (ii) discuss key challenges in the adoption of NGS testing in clinical practice; and (iii) adapt/modify the European Society for Medical Oncology guidelines for local use. Nine cancer types [breast cancer (BC), gastric cancer (GC), nasopharyngeal cancer (NPC), ovarian cancer (OC), prostate cancer, lung cancer, and colorectal cancer (CRC) as well as cholangiocarcinoma and hepatocellular carcinoma (HCC)] were identified, and the applicability of NGS was evaluated in daily practice and/or clinical research. Asian ethnicity, accessibility of NGS testing, reimbursement, and socioeconomic and local practice characteristics were taken into consideration. Results: The APODDC recommends NGS testing in metastatic non-small-cell lung cancer (NSCLC). Routine NGS testing is not recommended in metastatic BC, GC, and NPC as well as cholangiocarcinoma and HCC. The group suggested that patients with epithelial OC may be offered germline and/or somatic genetic testing for BReast CAncer gene 1 (BRCA1), BRCA2, and other OC susceptibility genes. Access to poly (ADP-ribose) polymerase inhibitors is required for NGS to be of clinical utility in prostate cancer. Allele-specific PCR or a small-panel multiplex-gene NGS was suggested to identify key alterations in CRC. Conclusion: This document offers practical guidance on the clinical utility of NGS in specific cancer indications from an Asian perspective.